Management Presentation
Attractive market fundamentals | Leadership and scale | Multiple growth drivers | Margin improvement | Attractive financial outlook | Compelling sustainability story
Top line growth momentum
continuing into 2023
Net sales by business
9M 2023, in USD bn
6.8
1.4
+6% 1
7.1
1.6
+11%
+5%
5.3
5.5
9M 2022
Generics
Biosimilars
9M 2023
Note: Net sales refer to net sales to third parties excluding sales to Novartis Group. Numbers may not add up due to rounding; 1. Growth vs. 9M 2022 in constant
currencies. For additional information regarding constant currencies, which is a non-IFRS measure, see "Appendix" starting on slide 31.
21
Management Presentation
Strong volume growth of 9%pts,
price erosion of -3%pts below prior
year
Continued momentum of Generics
business, driven by strong cough and
cold season and contribution from
recent launches
Biosimilars growing double digit, with
OmnitropeⓇ and HyrimozⓇ as key
contributors to growth
SANDOZView entire presentation